Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease-Reference-Cited by-同舟云学术

Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease

Published:2020-11 Issue:6 Volume: Page:174-179
ISSN:2687-8941
Container-title:JCO Global Oncology
language:en
Short-container-title:JCO Global Oncology

Author:

Singh Pawan Kumar¹,Kumar Rajender²,Bal Amanjit³,Gupta Nalini⁴,Kapoor Rakesh⁵,Prasad Kuruswamy Thurai¹,Singh Navneet¹

Affiliation:

1. Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

2. Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

3. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

4. Cytology and Gynecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

5. Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JGO.19.00357

Reference17 articles.

1. P2.03-053 A Five-Year Audit of EGFR and ALK Testing at a Tertiary Care Centre in North India: More Sensitive Methods Do Make a Difference!

2. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer

3. Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer

4. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

5. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodal treatment of oligometastatic non-small cell lung cancer;BMJ Case Reports;2023-12

2. Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort;Lung Cancer;2021-01

3. Afatinib/crizotinib/erlotinib;Reactions Weekly;2020-03